[Immunity against influenza virus infection].
Influenza A viruses of 16 serologically different hemagglutinin (HA) subtypes have been identified in waterfowl reservoirs, and the introduction of a novel HA subtype of avian viruses into the human population has the potential to generate the next pandemic strains. Both humoral and cellular immunity play important roles against influenza virus infection. Currently available inactivated influenza vaccines primarily induce subtype-specific serum neutralizing antibodies, but not cross-reactive cytotoxic T-cell response. Thus, vaccine-induced immunity is not fully effective against strains with serologically distinct HA. Our long-term goal is to develop a vaccine/therapy to induce highly crossreactive anti-influenza immunity, which may lead to the establishment of an ultimate strategy for the control of influenza.
Takada
Ayato
A
Research Center for Zoonosis Control, Hokkaido University.
D000818:Animals; D057134:Antibodies, Neutralizing; D001402:B-Lymphocytes / Q000276:immunology; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D006801:Humans; D009980:Influenza A virus / Q000145:classification / Q000276:immunology*; D007252:Influenza Vaccines; D007251:Influenza, Human / Q000453:epidemiology / Q000276:immunology* / Q000821:virology; D009092:Mucous Membrane / Q000276:immunology; D058873:Pandemics; D012703:Serotyping; D013601:T-Lymphocytes / Q000276:immunology; D014764:Viral Proteins
D057134:Antibodies, Neutralizing; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines; D014764:Viral Proteins; C483468:hemagglutinin, human influenza A virus